Volpara Health
With the appointment of a new CEO, Volpara Health set out to enhance trust with investors and transition from investor focus on cash burn to a future of sustainable value creation. Although the company wasn’t seeking additional capital, it faced a critical challenge: re-engaging long-term shareholders who had grown skeptical and demonstrating a clear, credible path to profitability.
To help reinforce the new CEO’s strategy, We. supported proactive communications with investors that aligned with Volpara’s renewed focus on operational efficiency and financial discipline. By mapping historical performance and shareholder sentiment, We. supported the CEO and CFO in engaging with investors on a forward-looking narrative that clearly articulated how Volpara would achieve profitable, sustainable growth.
This messaging was communicated through targeted investor engagement, media outreach and strategic events with industry leaders. The company’s leadership participated in speaking engagements, media interviews and investor roadshows to increase visibility and build confidence in the turnaround strategy.
As Volpara executed its strategy, investor confidence strengthened. The company not only met its financial milestones but exceeded them — reaching cash flow positivity ahead of schedule in early 2024.
This momentum drove a 47% increase in share price, attracted five new institutional investors, and ultimately positioned Volpara for a highly successful acquisition at a 48% premium. The takeover, unanimously approved by shareholders, marked a strong validation of the company’s turnaround and renewed investor trust.
“Breast Cancer Screen Company Volpara’s strategy is paying off with ebitda break-even on the horizon for the first time in 2024”
Fiona Rotherham
